Reduction in injection-related HIV risk after 6 months in a low-threshold methadone treatment program

AIDS Education and Prevention

Volumn 19, Issue 2, 2007, Pages 124-136

  Millson, Peggy ^a   Challacombe, Laurel ^a   Villeneuve, Paul J ^a   Strike, Carol J ^a,b   Fischer, Benedikt ^a,b   Myers, Ted ^a   Shore, Ron ^c   Hopkins, Shaun ^d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c Center for Addiction and Mental Health ^*  (Canada)

^d The Works   (Canada)

^e Toronto Department of Public Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG; METHADONE; OPIATE;

ADULT; ARTICLE; BEHAVIOR CHANGE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH BEHAVIOR; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; NEEDLE; OBSERVATIONAL STUDY; PREVALENCE; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; METHADONE; MIDDLE AGED; ONTARIO; RISK ASSESSMENT; RISK-TAKING; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 34247397900     PISSN: 08999546     EISSN: None     Source Type: Journal    
DOI: 10.1521/aeap.2007.19.2.124     Document Type: Article

References (41)

1. Aquillo, W.S. (1997). Privacy effects on self-reported drug use: Interactions with survey mode and respondent characteristics. NIDA Research Monograph, 167, 383-415.
2. Brands, J., Brands, B., & Marsh, D. (2000). The expansion of methadone prescribing in Ontario, 1996-97. Addiction Research, 8, 485-496.
3. Burns, S.M., Brettle, R.P., Gore, S.M., Peutherer, J.F., & Robertson, J.R. (1996). The epidemiology of HIV infection in Edinburgh related to the injecting of drugs: an historical perspective and new insight regarding the past incidence of HIV infection derived from retrospective HIV antibody testing of stored samples of serum. Journal of Infectious Diseases, 32(1), 53-62.
4. College of Physicians and Surgeons of Ontario. (2001). Methadone Maintenance Guidelines. Retrieved October 1, 2005, http://www.cpso.on.ca/ publications/methguide.htm
5. Darke, S. (1998). Self-report among injecting drug users: A review. Drug and Alcohol Dependence, 51, 253-263.
6. Des Jarlais, D.C., Choopanya, K., Vanichseni, S., Plangsringarm, K., Sonchai, W., & Carballo, M. et al. (1994). AIDS risk reduction and reduced HIV seroconversion among injection drug users in Bangkok. American Journal of Public Health, 84(3), 452-5.
7. Des Jarlais, D.C., Friedmann, P., Hagan, H., & Friedman, S.R. (1996). The protective effect of AIDS related behavioral change among injection drug users: A cross national study. WHO Multi-Centre Study of AIDS and Injecting Drug Use. American Journal of Public Health, 86(12), 1780-5.
8. Finch, E., Groves, I., Feinmann, C., & Farmer, R. (1995). A low-threshold methadone stabilisation programme description and first stage evaluation. Addiction Research, 3(1), 63-71.
9. Fischer, B. (2000). Prescriptions, power and politics: The turbulent history of methadone maintenance in Canada. Journal of Public Health Policy, 21(2), 187-210.
10. Gibson, D.R., Flynn, N.M., & McCarthy, J.J. (1999). Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS, 13, 1807-1818.
11. Gibson, D.R., Flynn, N.M., & Perales, D. (2001). Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS, 15(11), 1329-1341.
12. Grella, C.E., Anglin, M.D., & Annon, J.J. (1996). HIV risk behaviors among women in methadone maintenance treatment. Substance Use and Misuse, 31(3), 277-301.
13. Hartgers, C., van den Hoek, A., Krijnen, P., & Coutinho, R.A. (1992). HIV prevalence and risk behavior among injecting drug users who participate in 'low-threshold' methadone programs in Amsterdam. American Journal of Public Health, 82(4), 547-551.
14. Health Canada. (2004). I-Track: enhanced surveillance of risk behaviors among injecting drug users in Canada. Pilot Survey Report, February 2004 Retrieved October 1, 2005, from Health Canada Website Access: http://www.phac-aspc.gc.ca/i-track/psr-rep04/pdf/i- track_pilot_survey_report_feb-2004_e.pdf
15. Health Canada. (2002). Reducing the harm associated with injection drug use in Canada. Federal, Provincial and Territorial Advisory Committee on Population Health. Retrieved August 22, 2005, from Health Canada Website Access: http://www.hc-sc.gc.ca/ahc-asc/pubs/drugs-drogues/injection/index _e. html
16. Kerr, T., Wood, E., Small, D., Palepu, A., & Tynall, M.W. (2003). Potential use of safer injecting facilities among injection drug users in Vancouver's Downtown Eastside. Canadian Journal of Public Health, 169(8), 759-763.
17. Kilpatrick, B., Howlett, M., Sedgwick, P., & Ghodse, A.H. (2000). Drug use, self report and urinalysis. Drug and Alcohol Dependence, 58, 111-116.
18. Klingemann, H.K.H. (1996). Drug Treatment in Switzerland: Harm reduction, decentralization and community response. Addiction, 91(5), 723-736.
19. Ksobiech, K. (2003). A meta-analysis of needle sharing, lending and borrowing behaviors of needle exchange program attendees. AIDS Education and Prevention, 15(3), 257-268.
20. Latkin, C.A., Sherman, S., & Knowlton, A. (2003). HIV prevention among drug users: Outcome of a network-oriented peer outreach intervention. Health Psychology, 22(4), 332-339.
21. Marsch, L.A. (1998). The efficacy of methadone maintenance interventions in reducing illicit opioid use, HIV risk behavior and criminality: A meta-analysis. Addiction, 93(4), 515-532.
22. McLellan, A.T., Luborsky, L., Woody, G., & O'Brien, C.P. (1980). An improved diagnostic evaluation instrument for substance abuse patients: Addiction Severity Index. The Journal of Nervous and Mental Disease, 168(1), 26-33.
23. National Institute of Health National Consensus Development Panel on Effective Medical Treatment of Opioid Addiction. (1998). Effective medical treatment of opioid addiction. Journal of the American Medical Association, 280(22), 1936-1943.
24. Poshyachinda, V. (1993). Drug injecting and HIV infection among the population of drug abusers in Asia. BulletinonNarcotics, 45(1), 77-90.
25. Prendergast, M.L., Urada, D., & Podus, D. (2001). Meta-analysis of HIV risk reduction interventions within drug abuse treatment programs. Journal of Consulting and Clinical Psychology, 69(3), 389-405.
26. Ryrie, I.W., Dickson, J., Robbins, C., Maclean, K., & Climpson, C. (1997). Evaluation of a low-threshold clinic for opioid dependent drug users. Journal of Psychiatric andMental Health Nursing, 4, 105-110.
27. Schechter, M.T. (2002). NAOMI-Her Time Has Come. Journal of Urban Health: Bulletin of the New York Academy of Medicine, 79(2), 164-165.
28. Sorensen, J.L., & Copeland, A.L. (2000). Drug abuse treatment as an HIV prevention strategy: a review. Drug and Alcohol dependence, 59, 17-31.
29. Strathdee, S.A, Patrick, D.M., Currie, S.L., Cornelisse, P.G., Rekart, M.L., Montaner, J.S., et al. (1997). Needle exchange is not enough: Lessons from Vancouver Injecting Drug Use Study. AIDS, 11, F59-F65.
30. Strike, C., Challacombe, L., Villeneuve, P., Fischer, B., Myers, T., Shore, R., et al. (2004). The validity of self-reported reductions in drug use among participants of low-threshold methadone programs. Canadian Journal of Infectious Diseases, 15(Suppl. A), 359P.
31. Strike, C., Urbanoski, K., Fischer, B., Marsh, D., & Millson, M. (2005). Policy changes and the methadone treatment system for opioid dependence in Ontario, 1996 to 2001. Journal of Addictive Diseases, 24(1), 39-51.
32. Strike, C.J., O'Grady, C., Myers, T., & Millson, M. (2004). Pushing the boundaries of outreach work: The case of needle exchange outreach programs in Canada. Social Science and Medicine, 59(1), 209-219.
33. Torrens, M., Castillo, C., & Perez-Sola V. (1996). Retention in a low-threshold methadone maintenance program. Drug and Alcohol Dependence, 41, 55-59.
34. van Ameijden, E.J.C., van den Hoek, J.A.R., van Haastrecht, H.J.A., & Coutinho, R.A. (1992). The harm reduction approach and risk factors for human immunodeficiency virus (HIV) seroconversion in injecting drug users, Amsterdam. American Journal of Epidemiology, 136(2), 236-243.
35. van Ameijden, E.J.C., van den Hoek, J.A.R., & Coutinho, R.A. (1994). Injecting risk behavior among drug users in Amsterdam, 1986 to 1992, and its relationship to AIDS prevention programs. American journal of public health, 84, 275-281.
36. van Ameijden, E.J., Langendam, M.W., & Coutinho, R.A. (1999). Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. Addictive Behaviors, 24(4), 559-563.
37. Ware, J.E., & Sherbourne, C.D. (1992). The MOS 36-item short-form health survey (SF-36)-I: Conceptual framework and item selection. Medical Care, 30(6), 473-483.
38. Wood, E., Kerr, T., Montaner, J.S., Strathdee, S.A., Wodak, A., Hankins, C.A., et al. (2004). Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infectious Diseases, 4, 301-305.
39. Wood, E., Kerr, T., Small, W., Li, K., Marsh, D.C., Montaner, J.S., et al. (2004). Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. Canadian Medical Association Journal, 171(7), 731-734.
40. Wood, E., Tyndall, M.W., Li, K., Lloyd-Smith, E., Small, W., Montaner, J.S.G., et al. (2005). Do supervised injecting facilities attract higher-risk injection drug users? American journal of preventative Medicine, 29(2), 126-130.
41. Yancovitz, S.R., Des Jarlais, D.C., Peyser, N.P., Drew, E., Friedmann, P., Trigg H.L., et al. (1991). A randomized trial of an interim methadone maintenance clinic. American Journal of Public Health, 81(9), 1185-1191.